Pramlintide: A new tool in diabetes management.

Abstract	The amylin analogue pramlintide acts in concert with insulin to regulate glucose metabolism. It reduces postprandial hyperglycemia by suppressing postprandial glucagon secretion, regulating gastric emptying, and reducing food intake. In clinical use, pramlintide reduces postprandial glycemic excursions and improves A(1c) without the weight gain and increased risk of hypoglycemia typically seen with intensification of diabetes therapy.
Authors	Laura L Want, Robert E Ratner
Journal	Current diabetes reports (Curr Diab Rep) Vol. 6 Issue 5 Pg. 344-9 (Nov 2006) ISSN: 1534-4827 [Print] United States
PMID	17076994 (Publication Type: Journal Article, Review)
Chemical References	Amyloid Hypoglycemic Agents Islet Amyloid Polypeptide Glucagon pramlintide
Topics	Amyloid (administration & dosage, therapeutic use) Diabetes Mellitus (drug therapy, pathology) Diabetes Mellitus, Type 1 (drug therapy, pathology) Diabetes Mellitus, Type 2 (drug therapy, pathology) Gastric Emptying (drug effects) Glucagon (metabolism) Humans Hypoglycemic Agents (administration & dosage, therapeutic use) Islet Amyloid Polypeptide Models, Biological Pancreas (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!